CNS Pharmaceuticals (CNSP) Notes Payables (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Notes Payables came in at $328571.0 in Q4 2025, up 0.77% YoY from $326072.0 in Q4 2024, and up 967.03% on a QoQ basis from $30793.0 in Q3 2025.
CNS Pharmaceuticals (CNSP) Notes Payables (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Notes Payables data on file, last reported at $328571.0 in Q4 2025.
- Quarterly Notes Payables rose 0.77% year-over-year to $328571.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $328571.0 (up 0.77% YoY) and the FY2025 annual result came in at $328571.0, up 0.77% from the prior year.
- Notes Payables grew to $328571.0 in Q4 2025, from $30793.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $409968.0 in Q4 2022 to a low of $30793.0 in Q3 2025.
- A 5-year average of $199046.8 and a median of $194128.0 in 2021 frame the typical range for Notes Payables.
- Annual changes were most pronounced in 2021 — Notes Payables soared 518.27% — and 2023, when it declined 26.63%.
- Tracing CNSP's Notes Payables over 5 years: stood at $387794.0 in 2021, then gained by 5.72% to $409968.0 in 2022, then declined by 26.63% to $300806.0 in 2023, then grew by 8.4% to $326072.0 in 2024, then climbed by 0.77% to $328571.0 in 2025.
- The last three Notes Payables figures came in at $328571.0 (Q4 2025), $30793.0 (Q3 2025), and $121767.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - |
| 10 | CNS Pharmaceuticals | 2.58 Mn | -4.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 328,571.00 |
| Sep 30, 2025 | 30,793.00 |
| Jun 30, 2025 | 121,767.00 |
| Mar 31, 2025 | 210,673.00 |
| Dec 31, 2024 | 326,072.00 |
| Sep 30, 2024 | 31,187.00 |
| Jun 30, 2024 | 123,248.00 |
| Mar 31, 2024 | 213,104.00 |
| Dec 31, 2023 | 300,806.00 |
| Sep 30, 2023 | 41,904.00 |
| Jun 30, 2023 | 166,396.00 |
| Mar 31, 2023 | 289,075.00 |
| Dec 31, 2022 | 409,968.00 |
| Sep 30, 2022 | 39,260.00 |
| Jun 30, 2022 | 156,397.00 |
| Mar 31, 2022 | 272,572.00 |
| Dec 31, 2021 | 387,794.00 |
| Sep 30, 2021 | 44,632.00 |
| Jun 30, 2021 | 177,583.00 |
| Mar 31, 2021 | 309,133.00 |